Table 3.
Univariate analysis for baseline characteristics and treatment factors
| Factor | Level | No. | Overall survival | Progression-free survival | Local control | Regional control of neck | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HRa | 95 % CIb | P value | HR | 95 % CI | P value | HR | 95 % CI | P value | HR | 95 % CI | P value | |||
| Age | <53 | 15 | 1 | 0.416 | 1 | 0.568 | 1 | 0.869 | 1 | 0.202 | ||||
| ≥53 | 18 | 2.480 | (0.258, 23.852) | 1.524 | (0.364, 6.387) | 0.848 | (0.119, 6.021) | 3.788 | (0.423, 33.948) | |||||
| Sex | Male | 22 | 1 | 0.746 | 1 | 0.623 | 1 | 0.730 | 1 | 0.515 | ||||
| Female | 11 | 0.689 | (0.072, 6.629) | 0.671 | (0.135, 3.325) | 0.679 | (0.070, 6.526) | 0.488 | (0.054, 4.369) | |||||
| EOCG-PSc | ≦1 | 24 | 1 | 0.962 | 1 | 0.103 | 1 | 0.208 | 1 | 0.004* | ||||
| 2 | 9 | 0.947 | (0.098, 9.104) | 2.981 | (0.743, 11.950) | 0.285† | (0.002, 2.670)† | 12.296 | (1.372, 110.198) | |||||
| T classification | 2 or 3 | 16 | 1 | 0.048* | 1 | 0.025* | 1 | 0.043* | 1 | 0.177 | ||||
| 4a | 17 | 8.832† | (0.942, 1170.638)† | 7.636 | (0.938, 62.177) | 9.113† | (0.972, 1208.026)† | 4.004 | (0.447, 35.865) | |||||
| N classification | ≤1 | 17 | 1 | 0.933 | 1 | 0.896 | 1 | 0.355 | 1 | 0.140 | ||||
| >2 | 16 | 1.088 | (0.153, 7.725) | 1.097 | (0.274, 4.393) | 0.356 | (0.037, 3.437) | 4.521 | (0.505, 40.472) | |||||
| Stage | III | 8 | 1 | 0.245 | 1 | 0.084 | 1 | 0.235 | 1 | 0.184 | ||||
| IVA–IVB | 25 | 3.047† | (0.325, 0403.808)† | 6.170† | (0.768, 798.247)† | 3.124† | (0.333, 414.256)† | 3.828† | (0.434, 502.762)† | |||||
| Treatment period | <84 | 18 | 1 | 0.232 | 1 | 0.238 | 1 | 0.188 | 1 | 0.453 | ||||
| ≥84 | 15 | 3.634 | (0.378, 34.949) | 2.329 | (0.555, 9.768) | 4.108 | (0.426, 39.601) | 1.98 | (0.330, 11.895) | |||||
| Irradiation period | <63 | 19 | 1 | 0.817 | 1 | 0.252 | 1 | 0.219 | 1 | 0.392 | ||||
| ≥63 | 14 | 1.260 | (0.176, 9.023) | 2.268 | (0.539, 9.524) | 3.741 | (0.387, 36.178) | 2.14 | (0.357, 12.817) | |||||
| Catheterization | Ipsilateral | 16 | 1 | 0.285 | 1 | 0.019* | 1 | 0.276 | 1 | 0.020* | ||||
| Bilateral | 17 | 3.218 | (0.334, 31.040) | 8.274 | (1.007, 67.954) | 3.276 | (0.336, 31.926) | 11.878† | (1.343, 1560.619)† | |||||
| Selected artery | LA | 6 | 1 | 0.954 | 1 | 0.159 | 1 | 0.170 | 1 | 0.319 | ||||
| LA-ECA | 18 | 0.770 | (0.069, 8.529) | 0.888† | (0.226, 4.853)† | 0.338† | (0.052, 2.193)† | 1.000† | (0.185, 9.985)† | |||||
| ECA | 9 | 0.655 | (0.041, 10.466) | 0.114† | (0.001,1.403)† | 0.122† | (0.001, 1.503)† | 0.192† | (0.001, 3.619)† | |||||
| Total dose of CDDPd | <PAe | 14 | 1 | 0.085 | 1 | 0.286 | 1 | 0.079 | 1 | 0.862 | ||||
| ≥PA | 19 | 6.711† | (0.715, 889.729)† | 2.373 | (0.476, 11.808) | 6.857† | (0.732, 908.802)† | 1.184 | (0.197, 7.118) | |||||
| Catheter infection | No | 29 | 1 | 0.415 | 1 | 0.165 | 1 | 0.011* | 1 | 0.490 | ||||
| Yes | 4 | 2.488 | (0.258, 24.000) | 3.042 | (0.611, 15.145) | 8.506 | (1.195, 60.560) | 2.176 | (0.241,19.649) | |||||
| Number of chemotherapies | 1 | 7 | 1 | 0.719 | 1 | 0.185 | 1 | 0.793 | 1 | 0.222 | ||||
| 2 | 26 | 0.661 | (0.068, 6.410) | 0.391 | (0.093, 1.642) | 0.748 | (0.077, 7.257) | 0.342 | (0.057,2.050) | |||||
* P < 0.05
† The hazard ratio, 95 % confidence interval, and P value were estimated using Cox regression with Firth’s penalized likelihood
aHazard ratio; b 95 % confidence interval; c Eastern Cooperative Oncology Group performance status; d CDDP, cisplatin; e planned amounts